What Is Stage 3 Lung Cancer?
Stage 3 lung cancer is a locally advanced disease. The cancer has grown beyond the lung and spread to nearby lymph nodes in the chest, but has not yet reached distant organs such as the brain, liver, or bones. It accounts for roughly 30% of new NSCLC diagnoses and is one of the most clinically complex stages to manage.
Stage 3 falls between early-stage disease (Stages 1 and 2, confined to the lung) and metastatic disease (Stage 4, spread to distant organs). The cancer has spread to lymph nodes within the chest, the mediastinal or hilar regions, but has not reached other body systems.
For NSCLC, Stage 3 is sub-divided into three sub-stages. For small cell lung cancer (SCLC), Stage 3 corresponds broadly to limited-stage disease, cancer confined to one side of the chest within a single radiation field.
Stage 3A
Stage 3A is locally advanced but may be surgically resectable in selected patients. It includes tumours that have spread to ipsilateral mediastinal or hilar lymph nodes (the same side as the primary tumour). Tumour size ranges from 3 cm to 7 cm. Some smaller tumours with invasion of the chest wall, pericardium, or phrenic nerve and same-side nodal spread also fall here.
Stage 3B
Stage 3B involves spread to contralateral mediastinal or hilar nodes (opposite side of the chest) or supraclavicular nodes (above the collarbone). Tumours may have grown into the mediastinum, heart, trachea, oesophagus, or major blood vessels. Surgery is not typically possible at this sub-stage.
Stage 3C
Stage 3C is the most advanced form of locally advanced lung cancer. It involves extensive invasion of critical chest structures combined with contralateral mediastinal or supraclavicular nodal spread. Tumours are typically 5 cm or larger with at least two nodules in the same or adjacent lung lobe.
Stage 3 Lung Cancer Symptoms
Stage 3 is the point at which many patients first develop noticeable symptoms. The tumour's size and pressure on nearby structures produce a wider range of features than earlier stages.
Respiratory Symptoms
- Persistent cough that worsens over time or does not resolve
- Coughing up blood or blood-tinged mucus (haemoptysis)
- Shortness of breath, even at rest
- Wheezing or noisy breathing caused by partial airway blockage
- Recurrent chest infections or pneumonia in the same lung area
Chest and Structural Symptoms
- Chest pain or tightness, particularly when breathing deeply
- Hoarseness caused by pressure on the recurrent laryngeal nerve
- Difficulty swallowing (dysphagia) due to tumour pressing on the oesophagus
- Swelling of the face, neck, or arms, a sign of superior vena cava (SVC) syndrome
General and Systemic Symptoms
- Unexplained fatigue and unintentional weight loss
- Shoulder or arm pain in Pancoast tumours at the apex of the lung
- Drooping eyelid, constricted pupil, and reduced sweating on one side of the face - signs of Horner syndrome
Not all patients experience every symptom. Any persistent or unexplained respiratory symptom should be investigated promptly.
How Is Stage 3 Lung Cancer Diagnosed?
Accurate staging is especially important at Stage 3, because the choice between surgery and non-surgical treatment depends on the precise extent of lymph node involvement.
- Chest X-ray: Often the first imaging test; may show a mass or enlarged lymph nodes.
- CT scan of the chest and abdomen: Defines tumour size, location, and the extent of nodal spread.
- PET-CT scan: It highlights active cancer areas and helps check if the disease has spread to other parts of the body.
- Brain MRI: Performed for all Stage 3 patients to rule out brain metastases before treatment planning.
- Endobronchial ultrasound (EBUS): Biopsies mediastinal lymph nodes to confirm N2 or N3 status, a critical step in determining operability.
- Tissue biopsy: Confirms histological subtype and provides tissue for biomarker testing.
- Biomarker testing: EGFR, ALK, ROS1, KRAS, and PD-L1 are tested on biopsy tissue, as results directly influence which treatments are used.
Stage 3 Lung Cancer Treatment
Treatment depends on the sub-stage, lung function, performance status, and biomarker results. A multidisciplinary team, thoracic surgeon, medical oncologist, radiation oncologist, and pulmonologist, is involved in every Stage 3 decision.
Stage 3A - Potentially Resectable Disease
Stage 3A NSCLC may be surgically resectable when lymph node involvement is limited to single-station ipsilateral mediastinal nodes:
- Neoadjuvant chemotherapy (with or without immunotherapy) is given before surgery to shrink the tumour.
- Surgery (lobectomy or pneumonectomy) removes the primary tumour and sampled lymph nodes.
- Adjuvant targeted therapy or chemotherapy reduces recurrence risk post-surgery. Osimertinib (Tagrisso) is approved for adjuvant use in Stage 3A NSCLC patients with EGFR mutations, with five-year survival rates of up to 84.8% in high PD-L1 subgroups.
- Radiation therapy is added if cancer cells are found at the surgical margins.
Stage 3B and 3C - Unresectable Disease
For unresectable Stage 3B and 3C NSCLC, concurrent chemoradiation is the standard approach:
- Concurrent chemoradiation: Chemotherapy and radiation are delivered simultaneously over approximately six weeks, which is more effective than sequential treatment.
- Consolidation immunotherapy with durvalumab (Imfinzi): After completing chemoradiation, patients whose cancer has not progressed may be given durvalumab (Imfinzi) for up to a year. This approach, supported by the PACIFIC trial, has been shown to help people live longer and delay disease progression.
- Biomarker-guided maintenance: Some patients may receive further systemic therapy based on mutation status.
Limited-Stage SCLC
Limited-stage SCLC, broadly equivalent to Stage 3 NSCLC, is treated with concurrent platinum-etoposide chemotherapy plus thoracic radiation. Prophylactic cranial irradiation (PCI) is offered to patients who respond well to reduce the risk of brain metastases.
Stage 3 Lung Cancer Prognosis and Survival Rate
Five-Year Survival by Sub-Stage
Survival rates for Stage 3 NSCLC differ significantly by sub-stage:
- Stage 3A: approximately 36% five-year survival
- Stage 3B: approximately 26% five-year survival
- Stage 3C: approximately 13% five-year survival
The American Cancer Society's SEER database reports a 40% five-year relative survival for regional-stage NSCLC overall (patients diagnosed 2015-2021). For regional-stage SCLC, the five-year rate is around 20%.
Factors That Affect Prognosis
- Sub-stage: 3A has a significantly better outlook than 3B or 3C.
- Age: Patients under 65 tend to have longer survival.
- Performance status: Patients fit enough for multimodal treatment do substantially better than those who can only receive single-modality therapy.
- Treatment received: Concurrent chemoradiation outperforms sequential therapy. Adding durvalumab further improves survival; a 2022 study found a median survival of nearly 47 months in Stage 3 NSCLC patients treated with immunotherapy and chemotherapy combined.
- Biomarker profile: EGFR-mutated Stage 3A patients treated with adjuvant osimertinib show markedly improved long-term outcomes.
Is Stage 3 Lung Cancer Curable?
Stage 3 is considered potentially curable in selected patients, particularly Stage 3A cases with complete surgical resection. Even in unresectable disease, chemoradiation followed by durvalumab is given with curative intent, and long-term remissions do occur.
Conclusion
Stage 3 lung cancer is an advanced stage, but timely care can still improve outcomes. A clear understanding of symptoms, sub-stages, and treatments supports informed decisions. Early attention to warning signs can make a meaningful difference in disease management.
If you have concerns, please consult our lung specialist immediately.
